Evidence map›Paper›PMID 39349391›Full record

ReviewThe oncologist2025

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

Sandra Castaño-Díez, José Ramón Álamo, Mònica López-Guerra, Marta Gómez-Hernando, Inés Zugasti, Carlos Jiménez-Vicente, Francesca Guijarro, Irene López-Oreja, Daniel Esteban, Paola Charry and 17 more

Abstract readCase ReportsReview
In one paragraph

Review in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical management of CMML-State of the art.British journal of haematology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Sandra Castaño-DíezHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.ORCID 0000-0001-9044-4665
José Ramón ÁlamoHematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Mònica López-GuerraInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Marta Gómez-HernandoHematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Inés ZugastiHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Carlos Jiménez-VicenteHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Francesca GuijarroInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Irene López-OrejaHematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Daniel EstebanHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Paola CharryHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Víctor TorrecillasUniversitat Barcelona, Barcelona, Spain.
Lucia Mont-de TorresUniversitat Barcelona, Barcelona, Spain.
Albert Cortés-BullichHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Álex BatallerHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Ares GuardiaHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Daniel MunárrizHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Esther CarceleroPharmacy Service, Hospital Clínic Barcelona, Barcelona, Spain.
Gisela RiuPharmacy Service, Hospital Clínic Barcelona, Barcelona, Spain.
Ana TrigueroHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Natalia TovarHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Dolors VelaHematology Department, Hospital General de Granollers, Granollers, Spain.
Silvia BeàInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Dolors CostaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Dolors ColomerInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Maria RozmanInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Jordi EsteveHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Marina Díaz-BeyáHematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Funding

Instituto de Salud Carlos III (ISCIII) FIS PI19/01476Spanish Ministry of Education (VTM)
6 · The paper itself

Abstract

The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether CMML with NPM1 mutation (NPM1mut) should be diagnosed as AML. Nowadays, it is a subject of discussion because of its diagnostic and therapeutic implications. Therefore, we describe a case of a patient diagnosed with CMML NPM1mut and briefly review the literature to highlight the uncertainty about how to classify a CMML with NPM1 mutation. We emphasize the importance of a comprehensive molecular study, which is crucial to optimize the individualized treatment of patients, enabling them to access targeted therapies.

Indexed as

Leukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMutationNuclear ProteinsHumansNucleophosminNPM1 protein, humanNuclear ProteinsNucleophosminacute myeloid leukemiaAMLchronic myelomonocytic leukemiaCMMLCMML treatmentNPM1NPM1 CMMLNPM1mut CMML

Identifiers

PMID39349391
PMCPMC11884738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.